secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2024-07-19T23:59:59+00:00
Accession:  0001558370-24-009903
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech's Urica sells gout drug dotinurad to Crystalys for 35% equity and 3% royalty
--------------------------------------------------------------------------------

- Urica sold its URAT1 inhibitor dotinurad (gout treatment) and related IP to Crystalys Therapeutics.
- Urica received 35% of Crystalys' outstanding equity; cannot be diluted below 15% until Crystalys raises $150M in equity.
- Urica gets a securitized 3% royalty on future net sales of dotinurad plus nominal cost reimbursements.
- Urica has the right to appoint one director and one board observer to Crystalys' board.
- Crystalys must use commercially reasonable efforts to develop and commercialize dotinurad.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000155837024009903/0001558370-24-009903-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000155837024009903/fbio-20240715x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-009903

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer